🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sarah J. Westvold

Yale Cancer Center

ORCID: 0009-0004-2060-2137

Also affiliated with Yale University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.”.

Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.28
N/A
0DataRank · unranked
2 citations

Jessica B. Long, Sarah J. Westvold, Stephanie B. Wheeler, Lisa P. Spees, Michael Leapman +5 more

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.8747
N/A
0DataRank · unranked
3 citations

Jessica B. Long, Sarah J. Westvold, Michael Leapman, Lisa P. Spees, Michael E. Hurwitz +5 more

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae067
N/A
0DataRank · unranked
1 citations

Jessica B. Long, Sarah J. Westvold, Khushi Agnish, Hannah D. McManus, Michael Leapman +6 more

Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer(2025)10.1016/j.clgc.2025.102330
N/A
0DataRank · unranked
0 citations

Jessica B. Long, Sarah J. Westvold, Michael Leapman, Michael E. Hurwitz, Aaron Philip Mitchell +4 more